{"id":"W3131211776","doi":"10.1158/1538-7445.sabcs20-ot-28-01","title":"Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Taxane; Capecitabine; Metastatic breast cancer; Internal medicine; Oncology; Placebo; Nausea; Gastroenterology; Breast cancer; Trastuzumab; Phases of clinical research; Cancer; Surgery; Clinical trial; Colorectal cancer; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002283467,0.0006358415,0.002293929,0.0004870713,0.0003828672,0.0001129785,0.0005398244,0.000146194,0.006127949],"category_scores_gemma":[0.0005369845,0.000408372,0.000265983,0.002316283,0.0008106649,0.0004520295,0.0001856857,0.001070992,0.00001518302],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001009296,"about_ca_system_score_gemma":0.007318816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003819639,"about_ca_topic_score_gemma":0.01599267,"domain_scores_codex":[0.9934338,0.0005053278,0.001172763,0.001324539,0.002014607,0.001549009],"domain_scores_gemma":[0.9922964,0.002087468,0.0004568094,0.001259056,0.003277105,0.0006231596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9262109,0.004648824,0.0002625754,0.002310596,0.002607429,0.0005117531,0.002514741,0.001652837,0.01146954,0.00004138429,0.0004244809,0.0473449],"study_design_scores_gemma":[0.9331393,0.004328281,0.0002203616,0.002881852,0.0007499559,0.0003300779,0.01696181,0.0002340298,0.03657933,0.0001093776,0.003853554,0.0006121118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708546,0.007678579,0.001225573,0.002843106,0.0003389457,0.01582374,0.0006634279,0.0001226113,0.0004494041],"genre_scores_gemma":[0.9660773,0.001209744,0.002120318,0.0002434427,0.0005051324,0.02119205,0.00006955246,0.0002621081,0.008320299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04673279,"threshold_uncertainty_score":0.9998368,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1485206845789407,"score_gpt":0.4857765730134932,"score_spread":0.3372558884345525,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}